Unbalanced risk-benefit analysis of ADHD drugs – Authors' reply

Please use this identifier to cite or link to this item: https://oxfordhealth-nhs.archive.knowledgearc.net/handle/123456789/129

Title:	Unbalanced risk-benefit analysis of ADHD drugs – Authors' reply
Authors:	Cipriani, Andrea
Keywords:	Risk Assessment Attention Deficit Hyperactivity Disorder (ADHD)
Issue Date:	2018
Citation:	Cipriani, Andrea; Adamo, Nicoletta; Del Giovani, Cinzia; Goghill, David; Banaschewski, Tobias; Hollis, Chris; Zuddas, Alessandro; Simonoff, Emily; Cortese, Samuele. Unbalanced risk-benefit analysis of ADHD drugs – Authors' reply. Lancet Psychiatry Correspondence 2018 5(11)P871-873
Abstract:	Standardised mean differences can be difficult to translate into clinical practice. As reported in the Cochrane handbook, the mean difference (or more correctly, difference in means) measures the absolute difference between the mean value in two groups and then estimates the average amount that the experimental intervention changes in the outcome compared with that of the control intervention.
Description:	Published online at: DOI: 10.1016/S2215-0366(18)30396-1 This is an Open Access article under the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/). Copyright © 2018 Elsevier Ltd. All rights reserved.
URI:	https://oxfordhealth-nhs.archive.knowledgearc.net/handle/123456789/129
Appears in Collections:	Drug Therapy

Files in This Item:

File	Description	Size	Format
ADHD Author Response.pdf	ADHD drugs - Author's Response	54.83 kB	Adobe PDF	View/Open

DSpace JSPUI